Wellington Management Group LLP Has $225.53 Million Holdings in Bristol Myers Squibb Company $BMY

Wellington Management Group LLP decreased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 28.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,914,086 shares of the biopharmaceutical company’s stock after selling 1,592,910 shares during the quarter. Wellington Management Group LLP owned approximately 0.19% of Bristol Myers Squibb worth $225,530,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth about $1,947,272,000. Primecap Management Co. CA bought a new stake in Bristol Myers Squibb during the second quarter worth about $1,436,115,000. Legal & General Group Plc bought a new stake in Bristol Myers Squibb during the second quarter worth about $980,862,000. AQR Capital Management LLC boosted its position in Bristol Myers Squibb by 172.6% during the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock valued at $1,391,485,000 after purchasing an additional 16,332,924 shares during the last quarter. Finally, BlackRock Inc. grew its stake in Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Insider Buying and Selling

In related news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.05% of the company’s stock.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA approved Zenbexus (iberdomide), an oral therapy for adults with relapsed or refractory multiple myeloma when used with Johnson & Johnson’s Darzalex and dexamethasone. As the first approved CELMoD therapy in this setting, Zenbexus provides BMY with another potential oncology growth driver and may help diversify its product portfolio. Will ZENBEXUS’s First-in-Class CELMoD Approval Based on MRD-Negative CR Change Bristol Myers Squibb’s Narrative?
• Positive Sentiment: BMY paid Atrium Therapeutics a $15 million milestone after Atrium delivered a lead RNA compound for an undisclosed cardiovascular indication. The payment signals progress in the collaboration and could strengthen investor confidence in BMY’s cardiovascular research pipeline, although the program remains early-stage and details are limited. Can Atrium Therapeutics’ $15 Million Milestone From Bristol-Myers Squibb Validate its RNA Platform?
• Neutral Sentiment: BMY announced a follow-on study for its deucravacitinib program, indicating continued investment in autoimmune diseases. The update supports the company’s longer-term pipeline strategy but does not yet provide a near-term revenue catalyst. Bristol-Myers Squibb Extends Deucravacitinib Program
• Negative Sentiment: Cytokinetics reported a first-ever Phase 3 success in non-obstructive hypertrophic cardiomyopathy, intensifying competition with BMY’s Camzyos cardiovascular franchise. A successful rival could pressure Camzyos’ longer-term growth prospects. Cytokinetics Scores a First-Ever in Its Rivalry Against Bristol Myers
• Negative Sentiment: BMY ended its partnership with Cellares after determining that the company’s manufacturing platform could not produce Breyanzi at commercial scale. The decision may delay planned capacity expansion for the cell therapy and raises questions about Breyanzi’s ability to meet future demand. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth
• Negative Sentiment: SVP Phil Holzer sold 500 BMY shares for approximately $33,750. The relatively small transaction is unlikely to materially affect fundamentals, but it adds a modest negative signal. Bristol Myers Squibb SVP Phil Holzer Sells 500 Shares

Bristol Myers Squibb Stock Up 0.1%

BMY stock opened at $66.62 on Monday. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64. The business’s 50 day simple moving average is $61.76 and its 200 day simple moving average is $59.68. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The firm has a market capitalization of $136.09 billion, a PE ratio of 14.67, a PEG ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter last year, the firm posted $1.46 EPS. The company’s quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, research analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.8%. Bristol Myers Squibb’s payout ratio is presently 55.51%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Piper Sandler started coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set an “overweight” rating on the stock. Jefferies Financial Group cut shares of Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, August 5th. Sanford C. Bernstein upgraded shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 5th. Truist Financial reiterated a “buy” rating and issued a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, Guggenheim reissued a “buy” rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $66.06.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.